Individualized compounding enables precise dose adjustments, alternative dosage forms, and allergen/excipient avoidance for ...

Nearly half of 100 vulnerable medicines have at least one key starting material sourced exclusively from one country, ...

Cell and gene therapies (CGT) continue to advance in the pharmaceutical industry. Despite continued investment in R&D, the ...

Documented AI productivity gains include 28% faster target identification, 22% faster biomarker identification, and 20% ...

In today’s Pharmaceutical Executive Daily, UnitedHealth raises its full-year profit forecast following stronger-than-expected ...

Adjusted EPS was $7.23, materially ahead of expectations, and 2026 adjusted EPS guidance was raised to >$18.25, aided by ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...

A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products ...

“We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental ...

Early prescription volume signals uptake for an oral anti-obesity entrant, but competitive positioning versus oral ...